Daily Newsletter

08 August 2023

Daily Newsletter

08 August 2023

FDA approves first oral treatment for postpartum depression

Following the approval, Biogen plans for the commercial launch Zurzuvae (zuranolone) in Q4 2023.

Phalguni Deswal August 07 2023

The US Food and Drug Administration (FDA) has approved the once-daily oral Zurzuvae (zuranolone) for the treatment of postpartum depression.

Biogen plans to launch Zurzuvae in the last quarter of 2023 in the US, following the US Drug Enforcement Administration’s scheduling of Zurzuvae as a controlled substance, as per the company’s press release.

Zurzuvae is a neuroactive steroid (NAS) gamma-aminobutyric acid type A (GABA-A) receptor-positive allosteric modulator (PAM), which acts on the GABA-inhibiting pathway to regulate brain function.

The drug is being co-developed by Sage Therapeutics and Biogen as part of a global collaboration and licence agreement for Zurzuvae and SAGE-324. As part of the deal, both companies will share Zurzuvae’s developmental costs and revenues in the US while Biogen will hold these rights outside the US, excluding Japan, Taiwan, and South Korea.

The approval for Zurzuvae is based on the two randomised placebo-controlled Phase III trials (NCT02978326 and NCT04442503). Both the studies met their primary endpoints by achieving a reduction in the depression assessment scale, Hamilton Rating Scale for Depression (HAMD-17), at day 15, compared to the baseline.

The most common side effects associated with Zurzuvae are somnolence or sleepiness, dizziness, diarrhoea, fatigue, and urinary tract infection.

The approval news for Zurzuvae was accompanied by a disclosure that Biogen received a complete response letter (CRL) regarding the therapy’s new drug application (NDA) in another indication, major depressive disorder (MDD). The FDA response cited the need for an additional trial or multiple studies to for generating evidence on Zurzuvae’s efficacy.

Last month, Biogen announced the high-profile acquisition of Reata Pharmaceuticals for $7.3bn. The latter’s pipeline includes Skyclarys (omaveloxolone), the only FDA-approved treatment for the genetic neuromuscular disorder Friedreich’s Ataxia.

In the press release, Postpartum Support International executive director Wendy N Davis: “[Zurzuvae] approval is welcome news for the estimated 500,000 women in the United States who report experiencing symptoms of this devastating and often misunderstood illness each year.”

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.